PacBio narrows 2026 revenue guidance to $155M-$160M, targets cash flow breakeven in 2028
FROM THE WIRE · SEEKINGALPHA.COM
Earnings Call Insights: Pacific Biosciences of California (PACB) Q3 2026 MANAGEMENT VIEW * “In the third quarter, we continued the launch of SPRQ-Nx chemistry. Over half of Revio consumable revenue came from customers using SPRQ-Nx.” (CEO, President & Director Mark Van Oene) *…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralThe narrowed guidance and the 2028 cash flow breakeven target matter to investors in this genomics stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01In the third quarter PacBio reported revenue of $40.6 million.
- 02Over half of Revio consumable revenue came from customers using SPRQ-Nx.
- 03The $345 list price for the 20x HiFi human genome helped finalize multiple strategic deals.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets